Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)
Conclusion
This large, prospective registry demonstrates that PRCA is rare with subcutaneous administration of either the new coated-stopper syringe presentation of Eprex®, or NeoRecormon® or Aranesp®. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - February 23, 2015 Category: Urology & Nephrology Authors: Macdougall, I. C., Casadevall, N., Locatelli, F., Combe, C., London, G. M., Di Paolo, S., Kribben, A., Fliser, D., Messner, H., McNeil, J., Stevens, P., Santoro, A., De Francisco, A. L. M., Percheson, P., Potamianou, A., Foucher, A., Fife, D., Merit, V., Tags: Chronic Kidney Disease Source Type: research
Darbepoetin alfa for anemia with myelodysplastic syndrome
Expert Review of Hematology, Ahead of Print. (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - January 13, 2015 Category: Hematology Tags: article Source Type: research
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
CONCLUSIONS: In the CKD setting, there is currently insufficient evidence to suggest the superiority of any ESA formulation based on available safety and efficacy data. Directly comparative data for the effectiveness of different ESA formulations based on patient-centred outcomes (such as quality of life, fatigue, and functional status) are sparse and poorly reported and current research studies are unable to inform care. All proprietary ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta) prevent blood transfusions but information for biosimilar ESAs is less conclusive. Compara...
Source: Cochrane Database of Systematic Reviews - December 8, 2014 Category: Journals (General) Authors: Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
[QuiPO: Who inject EPO?].
DISCUSSION: This simple questionnaire shows that despite efforts made to improve ESA self administration, a minority of patients are in fact proceeding to ESA self administration. Asking for a nurse, does not help patient to be independent, and increases health cost. Efforts have to be made in order to help patients for ESA self administration.
PMID: 25439107 [PubMed - in process] (Source: Nephrologie and Therapeutique)
Source: Nephrologie and Therapeutique - December 1, 2014 Category: Urology & Nephrology Authors: Vigneau C, Le Stum S, Isnard-Bagnis C, Choukroun G, Lemeur Y, Kamar N, Oger E Tags: Nephrol Ther Source Type: research
Cost Consequence Analysis Of Darbepoetin Alfa For The Treatment Of Anemia Due To Chronic Kidney Disease (Ckd) In Greece
Conduct an economic evaluation of darbepoetin alfa for the treatment of anaemia due to chronic kidney disease (CKD) compared to other erythropoiesis stimulating agents (ESAs) in patients on haemodialysis (HD) or peritoneal dialysis (PD) in Greece. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G. Kourlaba, I. Boletis, D. Goumenos, C. Iatrou, V. Papagiannopoulou, G. Tritaki, N. Maniadakis Source Type: research
Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
Conclusion
Mean Hb values remained within a narrow range following switching from PEG-Epo to DA in this population of hemodialysis patients. Time trends of mean Hb and DA dose indicate that physicians titrated DA doses post-switch, to attain Hb concentrations comparable to those attained pre-switch with PEG-Epo.
Funding
Amgen (Europe) GmbH, Zug, Switzerland. (Source: Advances in Therapy)
Source: Advances in Therapy - November 1, 2014 Category: Drugs & Pharmacology Source Type: research
Erythropoiesis-Stimulating Agent Use Among Non–Dialysis-Dependent CKD Patients Before and After the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Using a Large US Health Plan Database
Conclusions TREAT appears to be a watershed study that was followed by a marked decline in ESA prescribing for patients with CKD. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - October 29, 2014 Category: Urology & Nephrology Source Type: research
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review
Conclusion There are currently only few well-designed head-to-head RCTs investigating the efficacy and safety of MPG-EPO compared with other ESAs in non-dialysis-dependent patients. MPG-EPO therapy compared with darbepoetin alfa has demonstrated favorable effects of increasing and maintaining hemoglobin concentrations to recommended target levels. This mini-review is not conclusive due to limited number of studies. Therefore, the beneficial effects and tolerability of MPG-EPO among non-dialysis-dependent CKD patients should be further investigated, given the economic and clinical benefits of managing anemia in this populat...
Source: International Journal of Clinical Pharmacy - October 6, 2014 Category: Drugs & Pharmacology Source Type: research
Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients
Conclusions
Epoetin beta, darbepoetin alfa, and epoetin beta pegol are effective and well-tolerated agents for managing anemia in Japanese pre-dialysis CKD patients. The intervals of ESA administration to maintain a patient’s target hemoglobin were longer in the order of epoetin beta pegol > darbepoetin alfa > epoetin beta. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - October 1, 2014 Category: Urology & Nephrology Source Type: research
Concurrent administration of darbepoetin alfa, cyclosporine A, and prednisolone is useful for T cell large granular lymphocyte leukemia associated with myelodysplastic syndrome complicated by Coombs-negative hemolytic anemia
(Source: Annals of Hematology)
Source: Annals of Hematology - September 27, 2014 Category: Hematology Source Type: research
1499p * effectiveness of darbepoetin alfa (da) for chemotherapy-induced anaemia (cia) when initiated at haemoglobin (hb)
Conclusions: Our study suggests that DA effectively increases Hb levels and reduces time to Hb increase in patients for whom treatment was initiated at Hb ≤10 g/dL, as per current product labelling.Disclosure: M. Hedenus: Minor honoraria for temporary advisory boards for Takeda, Pharmacosmos,and Vifor; L. Belton: Contractor funded by Amgen; J. Terwey: Employee of Amgen (Europe) GmbH. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Pirker, R., Vansteenkiste, J. F., Hedenus, M., Hernandez, E., Belton, L., Terwey, J. Tags: supportive care Source Type: research
1508p * haemoglobin (hb) levels and quality of life (qol) in patients (pts) with symptomatic chemotherapy-induced anaemia (cia): the eaqua study
Conclusions: In our study, pts with solid tumours receiving DA per European indication for symptomatic CIA had a clinically meaningful improvement in both Hb levels and QoL.Disclosure: G. Tonini, J. Mouysset, B. Freier, J. van den Bosch, A. Bols and H.W. Tessen: Research funding from Amgen for eAQUA participation; C.B. Levaché: is voluntary Président of association called "association pour la recherche clinique de francheville", which received a payment on behalf of AMGEN to realize the e-aqua study; L. Belton: Contractor funded by Amgen; C. Bohac: Amgen Inc. employee and stockholder; J. Terwey: Amgen (Europe...
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Tonini, G., Mouysset, J., Freier, B., van den Bosch, J., Levache, C. B., Bols, A., Tessen, H. W., Belton, L., Bohac, C., Terwey, J. Tags: supportive care Source Type: research
1509p * additional haemoglobin (hb) and quality of life (qol) analyses from eaqua
Conclusions: In our study, many pts treated with DA per current European indication for symptomatic CIA had Hb increases ≥1 g/dL and/or QoL improvements within 6 weeks of starting treatment. QoL/Hb improvements were observed across tumour types. Relatively few pts required transfusions or iron supplementation during the study.Disclosure: G. Tonini: received Research funding from Amgen for eAQUA participation; J. Mouysset, M. Rotarski, M. Airoldi, C. Toganel and C. Christofyllakis: has received research funding from Amgen for eAQUA participation; D. Spaeth: has received research funding from Amgen for eAQUA participation...
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Tonini, G., Mouysset, J., Rotarski, M., Spaeth, D., Airoldi, M., Toganel, C., Christofyllakis, C., Belton, L., Bohac, C., Terwey, J. Tags: supportive care Source Type: research
1511p * sompas: a prospective, non-interventional study (nis) of the management of symptomatic chemotherapy (ct)-induced anemia (cia) in patients (pts) with colorectal (crc), breast (bc) or lung cancer (lc) in austria (at) and switzerland (ch)
Conclusions: ESAs were used as per EORTC guidelines in 71% of pts, 51% of pts were initiated at Hb >10g/dL. Pts achieved a significant increase in Hb during ESA treatment; 90% had a Hb >10 g/dL. A large proportion of pts avoided RBCTs while treated with an ESA.Disclosure: G. Delmore: declares to be a member of the Amgen advisory board; C. Jaeger, C. Bast and I. Pezzani: declares to be an Amgen employee and to hold Amgen stock; M. Schmid: declares to be a member of the Amgen advisory board. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Eisterer, W., Trojan, A., Galid, A., Haslbauer, F., Delmore, G., Kolb, R., Jaeger, C., Bast, C., Pezzani, I., Schmid, M. Tags: supportive care Source Type: research
Hemoglobin Stability and Patient Compliance With Darbepoetin Alfa in Peritoneal Dialysis Patients After the Implementation of the Prospective Payment System.
Abstract
PURPOSE: Since the Centers for Medicare & Medicaid Services implemented the End-Stage Renal Disease Prospective Payment System, dialysis providers have increasingly focused on balancing resource utilization and quality outcomes for the treatment of anemia in patients undergoing peritoneal dialysis. Limited data exist regarding anemia management outcomes for these patients in US-based dialysis centers after the implementation of the new payment system.
METHODS: This was a retrospective, observational, cohort study of stable PD patients with end-stage renal disease who received darbepoet...
Source: Clinical Therapeutics - September 22, 2014 Category: Drugs & Pharmacology Authors: Pirkle JL, Paoli CJ, Russell G, Petersen J, Burkart J Tags: Clin Ther Source Type: research
